Key Takeaways
- • Cytospire Therapeutics secured £61 million ($83 million) in an oversubscribed Series A funding round led by 4BIO Capital, with participation from Servier Ventures, British Business Bank, Sound Bioventures, Criteria Bio Ventures, Abingworth, LifeArc Ventures, Modi Ventures, Medical Incubator Japan, and Pathway Bioventures.
- • The London-based biotech will deploy proceeds to advance its pipeline of first-in-class pan-gamma delta T-cell engagers, with lead candidate CYT X300 entering first-in-human clinical trials targeting EGFR-positive solid tumors including colorectal, head and neck, and non-small cell lung cancers.
- • Cytospire's therapeutic approach engineers immune cell engagers to bind and activate both tumor and blood resident gamma delta T cells, designed to target all gamma delta T-cell subtypes and generate anti-tumor responses across diverse tumor populations regardless of heterogeneity.
- • The platform addresses limitations of conventional CD3 T-cell engagers by leveraging gamma delta T cells' validated role in anti-cancer immunity, positioning the company to compete in the growing immunotherapy segment with a differentiated mechanism.
Summary
Cytospire Therapeutics, a London-based oncology immunotherapy company, announced its Series A funding achievement of £61 million ($83 million) on May 5, 2026. The round was oversubscribed, reflecting strong investor confidence in the company's approach to cancer treatment. The financing was led by 4BIO Capital and included a diverse syndicate of institutional investors, venture firms, and strategic partners spanning Europe, Japan, and North America.
The capital raise will fund advancement of Cytospire's proprietary pipeline of pan-gamma delta T-cell engagers, a novel class of immune cell modulators. The company's lead asset, CYT X300, is currently in investigational new drug-enabling preclinical studies and being manufactured for clinical trial initiation. Cytospire is planning first-in-human trials in patients with EGFR-positive solid tumors, a category encompassing colorectal cancer, head and neck cancers, and non-small cell lung cancer—indications representing significant unmet clinical need.
Cytospire's differentiated technology platform targets a mechanistic gap in existing immunotherapy. Rather than relying on conventional CD3 T-cell engagers, which face well-documented limitations in both efficacy and safety profiles, Cytospire's multispecific engager antibodies are engineered to simultaneously bind and activate gamma delta T cells resident in both tumors and peripheral blood. This approach is designed to engage the entire gamma delta T-cell compartment rather than selective subtypes, theoretically enabling anti-tumor responses across patient populations with heterogeneous tumor biology. According to CEO Natalie Mount, the company is building on emerging translational and clinical evidence demonstrating gamma delta T cells' critical role in anti-cancer immunity and their suitability as targets for next-generation cell engagers.
The investor syndicate reflects both specialized biotech expertise and strategic alignment with the immunotherapy sector. LifeArc Ventures, a UK-based venture investor focused on life sciences, participated as an existing investor, signaling early validation of the platform. The inclusion of Servier Ventures, the corporate venture arm of the French pharmaceutical company, suggests potential future partnership or commercialization pathways. The British Business Bank's participation underscores government backing for UK-based biotech innovation, while Geographic diversity among investors—including Medical Incubator Japan and global venture firms—indicates international recognition of the technology's commercial potential.
The capital raise will fund advancement of Cytospire's proprietary pipeline of pan-gamma delta T-cell engagers, a novel class of immune cell modulators. The company's lead asset, CYT X300, is currently in investigational new drug-enabling preclinical studies and being manufactured for clinical trial initiation. Cytospire is planning first-in-human trials in patients with EGFR-positive solid tumors, a category encompassing colorectal cancer, head and neck cancers, and non-small cell lung cancer—indications representing significant unmet clinical need.
Cytospire's differentiated technology platform targets a mechanistic gap in existing immunotherapy. Rather than relying on conventional CD3 T-cell engagers, which face well-documented limitations in both efficacy and safety profiles, Cytospire's multispecific engager antibodies are engineered to simultaneously bind and activate gamma delta T cells resident in both tumors and peripheral blood. This approach is designed to engage the entire gamma delta T-cell compartment rather than selective subtypes, theoretically enabling anti-tumor responses across patient populations with heterogeneous tumor biology. According to CEO Natalie Mount, the company is building on emerging translational and clinical evidence demonstrating gamma delta T cells' critical role in anti-cancer immunity and their suitability as targets for next-generation cell engagers.
The investor syndicate reflects both specialized biotech expertise and strategic alignment with the immunotherapy sector. LifeArc Ventures, a UK-based venture investor focused on life sciences, participated as an existing investor, signaling early validation of the platform. The inclusion of Servier Ventures, the corporate venture arm of the French pharmaceutical company, suggests potential future partnership or commercialization pathways. The British Business Bank's participation underscores government backing for UK-based biotech innovation, while Geographic diversity among investors—including Medical Incubator Japan and global venture firms—indicates international recognition of the technology's commercial potential.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.